Table 1.
Clinicopathological characteristics of patients included in study
| All patients | Development Set |
Validation set | |
|---|---|---|---|
| n | 123 | 65 | 58 |
| Median Age | 60 (30-83) | 61 (30-83) | 59 (33-80) |
| Pathology | |||
| IDC | 105 | 56 | 49 |
| ILC | 12 | 6 | 6 |
| Other | 3 | 3 | 0 |
| Histological Grade | |||
| 1 | 4 | 3 | 1 |
| 2 | 50 | 25 | 25 |
| 3 | 59 | 30 | 29 |
| unknown | 10 | 7 | 3 |
| ER positive | 86 | 48 | 38 |
| HER2 positive | 20 | 9 | 11 |
| HER2 testing site | |||
| Primary | 54 | 35 | 19 |
| Recurrent | 69 | 30 | 39 |
| Sites metastatic cancer visceral |
88 | 46 | 42 |
| non visceral | 35 | 19 | 16 |
| Adjuvant Chemotherapy | 39 | 31 | |
| Adjuvant Tamoxifen | 37 | 30 | |
| No prior metastatic chemo | |||
| 0 | 33 | 26 | |
| 1 | 15 | 12 | |
| 2 | 11 | 12 | |
| 3 | 5 | 5 | |
| 4 | 1 | 3 | |
| Prior HER2 directed therapy | 9 | 11 |
IDC – invasive ductal carcinoma, ILC invasive lobular carcinoma. No prior metastatic chemo – Number of prior courses of chemotherapy in the metastatic setting